GlobalData on MSN14h
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
Syndax Pharmaceuticals has announced that its Phase II trial of revumenib achieved its primary endpoint in certain patients ...
JPMorgan trims AbbVie target, removes from Analyst Focus List
JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...